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Abstract
Background: Serum free light chains (FLC) are sensitive 
biomarkers used for the diagnosis and management of 
plasma cell dyscrasias, such as multiple myeloma (MM), 
and are central to clinical screening algorithms and 
therapy response criteria. We have developed a portable, 
near-patient, lateral-flow test (Seralite®) that quantitates 
serum FLC in 10 min, and is designed to eliminate sample 
processing delays and accelerate decision-making in the 
clinic.
Methods: Assay interference, imprecision, lot-to-lot vari-
ability, linearity, and the utility of a competitive-inhibi-
tion design for the elimination of antigen-excess (‘hook 
effect’) were assessed. Reference ranges were calculated 
from 91 healthy donor sera. Preliminary clinical validation 
was conducted by retrospective analysis of sera from 329 
patients. Quantitative and diagnostic results were com-
pared to Freelite®.
Results: Seralite® gave a broad competitive-inhibition 
calibration curve from below 2.5 mg/L to above 200 mg/L, 
provided good assay linearity (between 1.6 and 208.7 
mg/L for κ FLC and between 3.5 and 249.7 mg/L for λ FLC) 
and sensitivity (1.4 mg/L for κ FLC and 1.7 mg/L for λ FLC), 
and eliminated anomalous results from antigen-excess. 
Seralite® gave good diagnostic concordance with Freelite® 
(Roche Hitachi Cobas C501) identifying an abnormal FLC 
ratio and FLC difference in 209 patients with newly diag-
nosed MM and differentiating these patients from normal 
healthy donors with polyclonal FLC.
Conclusions: Seralite® sensitively quantitates FLC and 
rapidly identifies clinical conditions where FLC are abnor-
mal, including MM.
Keywords: free light chains; multiple myeloma; near-
patient testing.
Introduction
The measurement of serum κ and λ immunoglobulin 
free light chains (FLC) is central to the diagnosis, prog-
nostication and monitoring of patients with plasma cell 
dyscrasias, such as multiple myeloma (MM). The abso-
lute levels of involved FLC (iFLC) versus uninvolved FLC 
[or the FLC ratio (κ:λ)] are used routinely to monitor 
light chain only (LCO) [1] and oligosecretory myeloma 
[2], as well as other plasma cell dyscrasias such as light 
chain amyloidosis [3], and light chain monoclonal gam-
mopathy of undetermined significance (MGUS) [4], 
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and their differentiation from healthy donors [5]. Addi-
tionally, the relatively short half-life of FLC (3–6 h) in 
blood compared to intact immunoglobulins (1–3 weeks) 
permits sensitive monitoring of response to anti-mye-
loma therapy and can identify early relapse in patients 
with intact immunoglobulin myeloma [6]. Accordingly, 
the availability of FLC testing over the last 15  years [7] 
has resulted in new patient screening algorithms and 
disease management criteria, and measurement of FLC 
is incorporated into the International Myeloma Working 
Group guidelines [8].
In the context of myeloma, rapid diagnosis and early 
disease intervention remains elusive. In the UK, 50% of 
newly presenting patients require three or more visits to 
the general practitioner (GP) before obtaining a hospital 
referral – the highest of 24 cancers assessed in a recent 
retrospective study [9]. As a result, 34% of 32,236 newly 
diagnosed myeloma patients presented as emergencies 
between 2006 and 2013, and 38% of these late presenta-
tions died within 6 months [10]. As a consequence, and 
by the time of hospital presentation, severe and life-
threatening myeloma-associated disease complications 
have been fostered that include infections from profound 
immunosuppression, skeletal fractures caused by bone 
loss, and acute renal failure from nephrotoxic iFLC [11]. 
In such cases, early diagnosis and treatment interven-
tion increases disease-free survival [11, 12], and the early 
identification and reduction of iFLC in cases of acute 
kidney injury by prompt therapy is essential for renal 
recovery [13, 14]. Early identification of an abnormal 
test result and commencement of therapy is thus critical 
[15, 16]. In the weeks, months and years after myeloma 
diagnosis, FLC monitoring remains vitally important for 
managing patients, whereby FLC testing can inform, at 
an early stage, whether early changes to treatment are 
needed, and can identify refractory myeloma and initia-
tion of new anti-myeloma therapy, particularly in cases 
of FLC escape [17].
Currently, FLC testing is conducted on either the 
first generation of FLC assays (Freelite®, The Binding 
Site, UK) which utilises latex-adsorbed sheep polyclonal 
anti-human FLC antisera, or a more recently launched 
assay (N Latex, Siemens, Germany), which uses mouse 
anti-human FLC monoclonal antibodies (mAbs). These 
assays require nephelometric or turbidimetric analys-
ers that are limited to large biochemistry departments 
or specialist centralised laboratories. Thus, FLC testing 
is often subject to undue delays of days or weeks whilst 
the sample is processed at these independent sites, 
meaning that clinical interventions – based on the inter-
pretation of the FLC results – are deferred. In addition 
to a clinical need for rapid, near-patient testing, any 
new FLC assay should overcome a number of analytical 
limitations that are associated with nephelometric and 
turbidimetric FLC measurements. As outlined by the 
International Myeloma Working Group [18], these prob-
lems include lot-to-lot inconsistency [19], poor sensitiv-
ity (i.e. Freelite® ‘gaps’) [20, 21], and variable specificity 
(i.e. cross reactivity with whole immunoglobulin-bound 
light chains) [22, 23], that together gives rise to differ-
ences in concordance between assays in the measure-
ment of absolute FLC concentrations [24–29]. In the 
assay described herein, we employ anti-FLC mAbs with 
excellent specificity, sensitivity and lot-to-lot consist-
ency, which have been shown to positively identify 
monoclonal FLC, where present and confirmed by immu-
nofixation electrophoresis (IFE), in over 14,000 consec-
utive patient samples [21]. A significant and undesirable 
feature of existing FLC assays is the well-described issue 
of antigen-excess arising from samples with high FLC 
levels which causes an underestimation of FLC concen-
tration, giving rise to significant non-linearity [27, 30, 
31]. Indeed, there are reports of Freelite® and N-Latex 
measuring ‘normal’ absolute FLC in samples with IFE 
positive M-protein at initial sample dilution followed 
by clinically ‘abnormal’ absolute FLC at higher sample 
dilution [27, 31–35]. Therefore, we have adopted a com-
petitive-inhibition format that is designed to eliminate 
antigen excess and prevent the phenomenon of false 
negatives in patients with MM – where the iFLC level can 
range from a few milligrammes to tens of grammes per 
litre – and has already demonstrated utility in a prior 
Luminex-based method [21].
In the present study, we describe the development 
and preliminary validation of a portable lateral-flow test 
that can rapidly and simultaneously quantitate serum κ 
and λ FLC in 10 min (Seralite®, Abingdon Health Ltd., UK). 
The assay incorporates a number of technical advances 
which are designed to overcome existing analytical prob-
lems in FLC testing.
Materials and methods
Test principle and procedure
Seralite® is a lateral flow device (LFD) for the quantification of κ 
and λ FLC levels in serum based on the principle of competition 
between FLC in a serum sample and immobilised purified FLC 
antigens for binding to gold-labelled anti-FLC mAbs; the anti-
FLC mAbs utilised in Seralite® [BUCIS 04 (anti-κ) and BUCIS 09 
(anti-λ)] were selected based on previous validation, described in 
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detail elsewhere [21]. The composition of the LFD is illustrated and 
described fully in Figure 1. To conduct the test, 100 μL of serum is 
added to 200 μL of sample buffer containing foetal bovine serum. 
From this, 100 μL is added to the sample application port of the 
LFD, which is immediately inserted into a Seralite® LFD reader 
(ADLxR3, Abingdon Health Ltd., York, UK). After a 10  min incu-
bation period at room temperature, the signal produced from the 
gold-labelled mAbs bound to the FLC antigens immobilised on the 
LFD membrane is inversely proportional to the amount of FLC in the 
sample; the Seralite® LFD reader converts the signal into mg/L of κ 
and λ FLC, and calculates the FLC ratio.
Assay calibration
Calibrator material was prepared using a pool of human serum sam-
ples containing monoclonal FLC (confirmed by IFE, and quantified 
by Freelite® using a Roche Hitachi Cobas® C501) from the University 
of Birmingham Clinical Immunology Service. To produce calibration 
curves the calibration material was diluted (κ at 1 in 2; λ at 1 in 1.5) 
in sample buffer, followed by subsequent serial two-fold dilutions in 
assay buffer. To establish the calibration range of Seralite®, calibra-
tion adjustments were made by measuring 91 normal human serum 
samples (UK National Health Service Blood Transfusion Service) 
that contained ‘normal’ polyclonal light chains (confirmed by IFE) 
on Freelite® and Seralite®. The calibration adjustments were made 
as follows: separate calibration curves are produced for each manu-
factured batch of devices using pooled serum containing elevated 
monoclonal FLC; separate pools for κ and λ FLC are used to derive 
the respective calibration curves. In the absence of an international 
reference material, these pools were initially tested on Freelite® 
to obtain a starting concentration, and based on these results, the 
pooled sera are diluted to set concentrations in foetal bovine serum 
to produce a calibrator set. The calibrator set is run in triplicate, 
across multiple readers. The mean reader response is calculated 
and plotted as a four-parameter logistic against the assigned values 
of the calibrator set. Ninety-one normal serum samples containing 
known concentrations of polyclonal FLC (established by Freelite®) 
are tested and then used to make minor adjustments to the original 
assigned concentration of the calibrator set. Following this process 
and to confirm performance, sets of internal control samples based 
on polyclonal and monoclonal FLCs that cover the calibration range 
are tested. Finally, when set quality control parameters are met, the 
Figure 1: Illustration of the structure of a Seralite® device. After isolating the serum from whole blood, the serum sample is mixed with 
pre-measured application buffer using a fixed-volume pipette provided with the Seralite® kit, the mixed sample is then added to the sample 
port where it then makes contact with the receipt pad. It then continues to flow onto a conjugate release pad where it rehydrates and mixes 
with gold-labelled anti-κ and anti-λ FLCs monoclonal antibodies (mAbs) and also a gold-labelled anti-biotin mAb. The mixture of sample 
and gold-labelled antibodies then migrates to a nitrocellulose membrane that contains immobilised antigens that have been passively 
absorbed to three lines. Line 1 contains a selection of purified κ FLC antigens and line 2 contains a selection of purified λ FLC antigens; 
these antigen preparations were isolated from human urine containing high levels of either κ or λ Bence Jones protein. κ and λ FLCs in the 
sample compete to bind to the gold-labelled anti-κ and anti-λ FLCs mAbs with the immobilised κ and λ antigens. Inhibition of anti-FLC mAbs 
binding to the test lines indicates presence of FLC in the sample: the signal produced from the gold-labelled mAbs bound to the purified 
FLC test lines is inversely proportional to the amount of FLCs in the sample. The gold-labelled anti-biotin mAb continues to flow across the 
membrane to line 3 where it binds to bovine serum albumin conjugated to biotin; this biotin system acts as a procedural control through 
normalising the response of the test lines. Ten minutes after the sample is first applied to the device, the reflectance of light at each of the 
three lines is analysed on a portable reader (ADxLR3®); to do this, the user inserts a Seralite® device into the device slot in the reader, and 
then commences the scan by pressing ‘analyse’. The ratio of the amount of absorbance at the test line (T: κ or λ) to the amount of absorb-
ance at the control line (C) is calculated as T/T+C to provide a normalised absorbance. The values of sample T/T+C for κ and λ are compared 
to those from stored κ and λ calibration curves to provide κ FLC and λ FLC levels for the sample (mg/L) and the κ:λ FLC ratio is calculated.
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curve parameters and batch lot number are converted into a bar code 
and the batch is released. Test results are read against these stored κ 
and λ FLC  calibration curves.
Assay dynamics
Linearity: Assay linearity was assessed by serially diluting two 
healthy donor serum samples spiked with purified κ or λ monoclo-
nal FLC two-fold in assay buffer; the purification of κ and λ FLC is 
described elsewhere [1]. A minimum of nine steps of dilutions were 
performed; three replicates for each dilution were measured and the 
mean values were analysed against the expected linear results.
Limit of detection: Assay buffer was measured using 20 replicates to 
obtain a ‘blank’ concentration and a normal serum sample was seri-
ally diluted 9 in 10. The limit of detection was determined by select-
ing the lowest κ and λ concentration of the normal sample detected 
above the mean blank value.
Imprecision: Test imprecision was assessed by calculating the 
mean intra-day and inter-day coefficient of variation percentages 
(CV%). For these analyses, three large volume samples with normal 
(containing polyclonal FLC), elevated and high levels (containing 
monoclonal FLC) of κ and λ FLC were obtained from a bioreposi-
tory at the University of Birmingham Clinical Immunology Service. 
All samples were analysed a total of four times per day: analysis 
was performed in duplicate, twice per day (with a 2-h gap between 
runs), for 11 days over a period of 28 days. To determine between 
reader precision, three samples with normal, elevated and high lev-
els of κ and λ FLC were used. Each sample was analysed 20 times 
on the same day and each LFD was read using three different LFD 
readers; CV% was calculated for each of the 20 replicates across 
the readers and averaged to provide an inter-reader CV% for each 
sample. All imprecision analyses were conducted on the same lot 
of reagents.
Analyte stability: To determine analyte stability using Seralite®, 
four samples with below normal, normal, elevated and high lev-
els κ and λ FLC were used and measured in triplicate at each time 
point. All samples were measured at baseline (hour/day 0) then ali-
quots were stored under different conditions. Samples were stored 
at room temperature (21–24 °C) and tested at 1, 8, 24, 48 and 72 h. 
Samples stored in the fridge between 3 and 5 °C were tested across 
a period of 4 consecutive days, then for an additional day 7  days 
from baseline. Aliquots of each sample were frozen on day 0 then 
tested daily for six consecutive days providing a total of six freeze 
thaw cycles.
Interference: To assess the susceptibility of Seralite® to inter-
ference, known quantities of common interference agents were 
added to serum samples containing normal κ (12.72 mg/L) and λ 
(10.88 mg/L) polyclonal FLC levels. Serum samples were individually 
spiked with purified (all obtained from Sigma Aldrich, UK): bilirubin 
(0.2 g/L), cholesterol (2.0 g/L), haemoglobin (2.0 g/L) and triglycer-
ide (10.0 g/L); and the following immunoglobulin proteins (purified 
by the University of Birmingham Monoclonal Antibody Production 
Service): IgG-κ (0.84 g/L), IgG-λ (0.32 g/L), IgA-κ (0.65 g/L), IgA-λ 
(0.15 g/L), IgM-κ (0.45 g/L), IgM-λ (0.38 g/L), κ FLC (0.53 g/L) or λ FLC 
(0.73 g/L); these concentrations represent the final concentration of 
interference agents in the sample.
Lot-to-lot consistency: Variability between batches of Seralite® was 
assessed by analysing 65 serum samples exhibiting FLC levels that 
covered the entire calibration range of the assay, using three con-
secutive lots of assay kits. The samples were healthy donor sera con-
taining polyclonal FLCs within the normal FLC reference range, or 
myeloma patient sera containing monoclonal FLC  identified by IFE. 
Data were analysed using Passing and Bablok regression.
Antigen excess: Seralite® was used to analyse 10 serum samples 
from MM patients, tested previously during routine clinical measure-
ment of FLC, that had been identified to give erroneously low results 
using Freelite® (Roche Hitachi Cobas® C501) due to antigen excess. 
Data are presented for each sample at the original standard dilution 
and with further dilution for both methods.
Reference ranges: Ninety-five serum samples were obtained from 
healthy random donors from the NHS Blood and Transplant service 
(NHSBT Birmingham, UK). All samples were first analysed for abnor-
mal FLC on Freelite® and creatinine (both on Roche Hitachi C501) to 
screen for impaired renal function, or monoclonal gammopathies 
or immune dysregulation: four patients were excluded on the basis 
of this screening. The remaining 91 samples were analysed using 
Seralite® to generate references ranges for κ and λ FLC, and the κ:λ 
ratio.
Clinical specificity: To compare FLC levels between the new near-
patient device and a commonly used laboratory-based immuno-tur-
bidimetric method, a range of stored (cryopreserved) patient samples 
were analysed retrospectively by Seralite® and Freelite®. 120 serum 
samples from patients with a range of conditions associated with 
abnormalities in FLC levels (but not monoclonal gammopathy) were 
analysed: rheumatoid arthritis (n = 18); systemic lupus erythemato-
sus (n = 16); Sjögren’s syndrome (n = 23); recurrent infections (n = 9); 
nephrotic syndrome (n = 18); vasculitis (n = 11); B-cell non-Hodgkin lym-
phomas (n = 12) or chronic lymphocytic leukaemia (n = 13). All patients 
were screened to confirm they did not have a monoclonal gammopathy 
by serum IFE, in conjunction with each patient’s clinical history.
Serum samples from 209  MM patients at disease presentation 
were measured for κ and λ FLC using both methods. Patients had 
been diagnosed with LCO (n = 122), IgG (n = 49) or IgA (n = 38) mye-
loma. Clinical results were compared between Seralite® and Freelite® 
using the κ:λ ratio. Discrepancies between methods were defined 
as any sample with an abnormal κ:λ ratio on one assay but not the 
other. Discrepant samples were investigated using serum and urine 
IFE and patient history.
Statistical analyses
Passing and Bablok regression and linearity analysis were conducted 
using the Microsoft Excel add-in Analyse-it software (version 4.60, 
Method Evaluation, www.analyse-it.com). Wilcoxon signed rank 
tests were used to compare FLC parameters between methods (IBM 
SPSS, Version 21). Figures were produced using SigmaPlot version 
12.0 (SystatSoftware Inc., USA) and GraphPad Prism (GraphPad 
 Software Inc., USA).
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Results
Calibration and assay dynamics
Representative calibration curves are illustrated in 
Figure  2A, where the assay range was between 1.7 and 
213.4 mg/L for κ FLC, and between 1.9 and 239.9 mg/L for 
λ FLC. A dynamic range of 2.5–200 mg/L for κ and λ FLC 
calibration curves was subsequently programmed into the 
Seralite® reader to (i) enable matching curves for κ and 
λ FLC and (ii) provide a fixed consistent range between 
future lots for absolute κ and λ FLC, and the FLC ratio. The 
limit of detection was 1.4 mg/L for κ and 1.7 mg/L for λ.
Representative assay linearity is presented in Figure 2B 
and C, where κ FLC was linear between 1.6 and 208.7 mg/L 
and λ FLC between 3.5 and 249.7 mg/L. The differences 
between expected linear and observed concentrations 
were calculated at all dilutions and the maximum differ-
ence between results was 7% for κ FLC and 10% for λ FLC.
Precision was assessed by measuring three samples 
with levels of FLC within, above and highly-elevated 
above the normal range. Across the three samples, intra-
day CV% was between 7.4 and 9.6% and inter-day CV% 
was between 3.6 and 7.1%. Inter-reader precision was also 
assessed using three samples and CV% between 2.0 and 
5.5% were observed. Precision data for all samples are 
provided in Supplementary Table 1.
Good stability was observed for FLC measured by 
Seralite® when samples of various concentrations were 
stored under different conditions. Supplementary Table 2 
describes the median changes from baseline in κ and λ FLC 
concentrations following storage at room temperature, 
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Figure 2: Representative κ and λ FLC calibration curves (A) showing the FLC test line/(test line+control line) value and FLC concentration 
(mg/L) generated by Seralite®. The calibration ranges illustrated by these curves are 213–1.7 mg/L for κ FLC and 240–1.9 mg/L for λ FLC. 
Examples of linearity for κ (B) and λ (C). Serum samples containing either κ or λ FLC monoclonal protein were serially diluted  two-fold in 
sample buffer. The solid line represents the linear (predicted) concentrations compared with the non-linear (acquired)  concentrations repre-
sented by a dashed line.
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when refrigerated and after freeze thaw cycles. Gener-
ally, median changes from baseline were  < 2 mg/L and the 
highest median change observed across conditions and 
samples was –7.8 mg/L in samples containing monoclonal 
FLC concentrations above 120 mg/L.
Assay interference tests showed minimal assay cross-
reactivity to potential interfering agents, and no more 
than a median 2.47 mg/L change was observed for κ FLC, 
and 2.23 mg/L for λ FLC (Supplementary Figure 1).
Assay lot-to-lot variability was assessed by analysing 
65 patient samples with varying FLC levels across the full 
range of the calibration curves (Supplementary Figure 2). 
Passing and Bablok regression analysis gave the following 
slopes (95% CI) and intercepts (95% CI), respectively: 1.06 
(0.96–1.23) and –0.67 (–3.30 to 0.83) for batch A vs. B; 1.02 
(0.92–1.11) and –1.29 (–2.76 to 0.66) for batch A vs. C; 0.94 
(0.88–1.01) and –0.82 (–0.39 to 1.75) for κ FLC; 0.92 (0.83–
1.03) and 0.53 (–0.52 to 1.41) for batch A vs. B; 0.94 (0.88–
1.02) and 0.28 (–0.37 to 1.05) for batch A vs. C; 1.06 (0.99–1.14) 
and –0.69 (–1.56 to 0.28) for λ FLC. The mean absolute dif-
ferences between batches for κ and λ,  respectively, were 5.5 
and 4.0 mg/L (batch A vs. B), 4.6 and 3.4 mg/L (batch A vs. 
C) and 3.8 and 3.4 mg/L (batch B vs. C).
To assess the elimination of antigen excess on 
Seralite®, samples from myeloma patients previously 
shown to give erroneously low results by Freelite® due 
to antigen excess where analysed on Seralite® (Supple-
mentary Table 3). Seralite® correctly identified all iFLC in 
these patients using the standard dilution; one sample 
exhibited a false negative on Freelite and the iFLC in that 
sample was correctly identified upon higher dilution of 
the sample.
Reference ranges
The values obtained for Seralite® and Freelite® from 
91 donor sera are presented in Figure 3. On Seralite®, 
the observed median (5%–95% range) for κ FLC was 
10.75 mg/L (5.25–22.66), λ FLC was 10.46 mg/L (3.96–25.13), 
the κ/λ FLC ratio was 1.13 (0.48–2.49), and the FLC differ-
ence (κ FLC minus λ FLC) was 1.07 mg/L (–6.48 to 6.96). 
On Freelite®, κ FLC was 11.24 mg/L (4.52–27.40), λ FLC was 
11.28 mg/L (6.63–17.55), the κ/λ FLC ratio was 0.99 (0.45–
1.6), and the FLC difference was –0.12 mg/L (–3.60 to 4.74). 
There were no significant differences in κ FLC, λ FLC, or 
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Figure 3: FLC parameters from 91 normal sera analysed using Freelite® and Seralite®. κ (A) and λ (B) FLC concentrations, the κ:λ ratio (C) and 
the FLC difference (dFLC) (D) are presented. Lines indicate the median.
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the FLC difference measured by Seralite® and Freelite®. 
However, the κ/λ FLC ratio was higher when measured by 
Seralite® compared to Freelite® (Z = –2.39, p = 0.017).
Clinical specificity
Sera from 120 patients with dysregulated polyclonal 
FLC levels arising from an array of clinical disorders 
were measured on Seralite® and Freelite®. As illustrated 
in Figure 4, elevated levels of both κ and λ FLC were 
found in the majority of patients when measured by both 
Seralite® and Freelite®. In general, Seralite® produced 
lower FLC values compared with Freelite®. On Seralite®, 
the observed median (5%–95% range) for κ FLC was 
22.75 mg/L (6.44–92.72) compared with 25.11 mg/L (4.54–
144.51) on Freelite® (Z = –2.24, p = 0.025). On Seralite®, both 
the κ/λ FLC ratio (0.96, 0.38–2.49) and FLC difference 
(–0.75, 37.41–44.33  mg/L) were lower than the κ/λ FLC 
ratio (1.22, 0.57–3.02) and FLC difference (3.73, –5.31 to 
76.87 mg/L) measured by Freelite® (Z = –3.45, p = 0.001 and 
Z = –4.67, p < 0.001, respectively). Alternatively, λ FLC levels 
were higher when measured by Seralite® compared with 
Freelite®, with values of 23.30 mg/L (5.78–86.41) and 18.72 
(7.47–58.52), respectively (Z = –3.51, p < 0.001).
Sera from 209 newly presenting myeloma patients 
were measured on Seralite® and Freelite®. Illustrated in 
Figure 5 are the absolute levels of κ FLC, λ FLC, κ:λ FLC 
ratio and FLC difference (iFLC–uninvolved FLC) in these 
patients. Seralite®. Levels of FLC parameters were signifi-
cantly lower on Seralite® compared with Freelite® (Z = –4.25 
to –8.20, p < 0.001 for all comparisons). The κ:λ FLC ratio 
5–95th reference range for Seralite® was applied for diag-
nostic purposes. In agreement with Freelite®, Seralite® 
gave an abnormal κ:λ FLC ratio in all patients (Figure 6).
Discussion
This study describes the development and initial valida-
tion of a rapid, fully-quantitative, near-patient lateral flow 
assay for the measurement of serum FLC. Seralite® has 
been designed to measure absolute κ and λ FLC levels and 
the FLC ratio in 10 min to enable ‘on-the-spot’ decision-
making and eliminate the dependence on sending patient 
samples to biochemistry departments or specialist labora-
tories where serum FLC are measured on complex analys-
ers in batches, usually not on a daily basis. This process 
incurs delays during sample shipment, testing and pro-
cessing and defers decisions about patient treatment.
As the diagnosis of MM necessitates a battery of tests 
[8], Seralite® may be used to ‘red flag’ patients with sus-
pected monoclonal gammopathy for prioritisation and 
accelerated testing of sample specimens at clinical labo-
ratories. Early detection of MM – and treatment of the 
acute clinical complication that initiated the hospitali-
sation – is highly prognostic for survival [12] and is par-
ticularly vital in cases of acute renal failure where early 
Figure 4: Comparison of the κ FLC (A) and λ FLC levels (B) from 120 patients analysed using Freelite® and Seralite®. Patients had condi-
tions associated with dysregulation of polyclonal FLCs: rheumatoid arthritis (n = 18); systemic lupus erythematosus (n = 16); Sjögren‘s 
syndrome (n = 23); recurrent infections (n = 9); nephrotic syndrome (n = 18); vasculitis (n = 11); B-cell non-Hodgkin lymphomas (n = 12); chronic 
 lymphocytic leukaemia (n = 13). Lines indicate reference ranges for each assay: κ FLC: 3.30–19.40 mg/L for Freelite® and 5.25–22.66 mg/L 
for Seralite®; λ FLC 5.71–26.30 mg/L for Freelite® and 3.96–25.1 mg/L for Seralite®.
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Figure 5: FLC parameters from multiple myeloma patient sera samples analysed using Freelite® and Seralite®. Samples included IgG (n = 49), 
IgA (n = 38) and LCO (n = 122) myeloma patients at disease presentation. Data shown are for involved FLC level, κ:λ FLC ratio and the differ-
ence between the involved and uninvolved FLC (dFLC) for patients with either κ (n = 130, A, B and C) or λ (n = 79, D, E and F) involved FLC. Lines 
indicate the median. *Seralite® values were significantly different to Freelite®, p < 0.001 for all comparisons.
Figure 6: Comparison of the κ:λ FLC ratio for serum samples from healthy donors (n = 91) and myeloma patients (n = 209) at disease presen-
tation obtained using Freelite® and Seralite®. Lines represent the diagnostic ranges for each assay: 0.26–1.65 for Freelite® and 0.5–2.5 for 
Seralite®.
reduction of nephrotoxic iFLC is critical for renal recovery 
[14]. In myeloma patients being monitored, iFLC levels can 
be used to identify efficacy of anti-myeloma therapy and 
can be used to exclude relapse until FLC levels increase, in 
which case, further laboratory testing can be prioritised to 
confirm active myeloma. FLC testing is especially impor-
tant in diagnosing cases of serum and urine IFE negative 
LCO myeloma and amyloidosis where there are few meas-
ures of disease activity beyond bone marrow examina-
tion, as well as LCO myeloma when serum IFE is negative 
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and no urine has been sent. It has also been established 
that serum FLC testing is more sensitive than urine, and 
is particularly important in monitoring LCO patients, 
patients with low levels of whole M-protein and for light 
chain escape [36]. To overcome the reliance on laboratory 
analysers for the measurement of FLC, Seralite® fulfils a 
number of important analytical and performance require-
ments. Firstly, as reported herein, Seralite® exhibits a 
broad calibration range from 2.5 to 200 mg/L for both κ 
and λ FLC. This extensive range enables accurate quan-
titation of healthy donor sera and similar enumeration of 
normal polyclonal FLC as the Freelite® assay [5]. We note 
that the Seralite® reference ranges reported herein are 
based on 90% ranges, whereas well-cited Freelite ranges 
are derived from 95% ranges [5]; accordingly, this may 
result in a higher proportion of Seralite® results falling 
outside its associated references ranges, as compared 
to Freelite® and its associated reference ranges. As with 
all clinical tests, it is important that end users establish 
normal ranges for their own laboratory. In addition to 
accurate enumeration of polyclonal FLC, the low limit 
of detection on Seralite® enables sensitive measure-
ment of low levels of FLC indicative of immunosuppres-
sion or immunoparesis and avoids the low-sensitivity 
‘gaps’ that are a feature of Freelite® [20, 21]. The ‘gaps’ are 
observed when levels of absolute FLC (e.g.  < 7 mg/L) in a 
patient specimen are below the initial measuring range of 
Freelite® using the automated dilution (e.g. 1 in 8); a sub-
sequent repeat of the neat sample then reveals that the 
sample is either  > 7 mg/L or  < 2 mg/L, presumably due to 
the non-linearity of FLC assays at low FLC levels [31]. This 
is a key limitation of Freelite® when monitoring patients 
with plasma cell dyscrasias because an ‘artefactual’ shift 
from 7 mg/L to 1 mg/L in the uninvolved Freelite® FLC level 
will cause an ‘artefactual’ seven-fold change in FLC ratio, 
thus potentiating incorrect clinical interpretation. On 
Seralite®, the initial upper-range of the assay is designed 
to enable the identification of large numbers of patients 
with abnormally high iFLC outside the normal reference 
range; a 1 in 20 dilution of patient sample extends the 
assay range to 4000 mg/L, thus quantitating the majority 
of patients with myeloma.
Although Seralite® provides similar diagnostic con-
cordance with Freelite® in myeloma patients, we note that 
Seralite® has a broader FLC ratio range than Freelite®, 
whereas absolute levels of κ and λ FLC measured on 
Seralite® are lower than Freelite®. Overestimation of 
Freelite® in samples containing monoclonal FLC has been 
reported previously [37], and a recent study showed that 
this may be a feature of nephelometric assays, as both N 
Latex and Freelite® nephelometric assays substantially 
overestimated FLC compared to a mass spectrometry 
method [38]. As a result of the overestimation of Freelite® 
(and N Latex) nephelometric methods, it is not possi-
ble to apply a calibration correction to harmonise inter-
assay differences, and as a consequence, it is unlikely 
that FLC assays (Seralite®, Freelite®, or N Latex) can be 
used interchangeably in monitoring individual patients 
[39]. Currently, no international standard is recognised or 
available, thus laboratories and clinical centres seeking to 
change FLC method should analyse any new sample on 
the old assay (i.e. the assay being replaced) and the new 
assay concurrently so that a new FLC benchmark can be 
established for each individual patient [39, 40]. A conse-
quence of the exponential increase in FLC levels on exist-
ing FLC assays – as outlined by the International Myeloma 
Working Group – is the non-linearity of sample dilutions 
[18]. Seralite® results presented herein show good lin-
earity on serial dilutions of sera containing high levels 
of monoclonal FLC. A related problem that affects exist-
ing FLC assays on certain analysers – that Seralite® over-
comes – is the problem of antigen excess. In this study, we 
report one Freelite® false negative, and numerous occa-
sions where high FLC levels were initially low on Freelite® 
that subsequently gave higher results when less sample 
(i.e. more dilute sample) was added. To address this issue, 
Seralite® has a competitive inhibition format that elimi-
nates this risk, and any samples with high iFLC above the 
calibration range of the assay are identified as being above 
200 mg/L and should be re-diluted. This is an important 
development that will ensure, not only that false nega-
tives are reduced which delay diagnosis, but that patients 
can be monitored accurately throughout therapy without 
confusion, e.g. during efficacious anti-myeloma therapy 
where the assay should report falling iFLC levels rather 
than giving erroneously higher iFLC levels [35].
Incorporated into Seralite® are extensively-validated 
anti-FLC mAbs, which have previously been shown to 
have excellent specificity, sensitivity, and lot-to-lot con-
sistency [21], and the incorporation of these mAbs into 
Seralite® yielded similar results with minimal interference 
and good inter-test consistency found between batches. 
These archetypal characteristics of mAbs overcome many 
limitations of polyclonal antibody-based assays [18], 
but, despite these many advantages, their application 
and utility in FLC assays has been a contentious issue in 
recent years [25, 41]. This is partly founded on the expe-
rience of groups, including ours, where mAbs have been 
produced that were unsuccessful in detecting FLC from 
substantially all neoplastic cell clones, or did not analyse 
performance against a sufficiently high number of diverse 
patient samples. However, in recent years, we have shown 
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that mAbs – which target a specific site on the constant 
region domain (that is ‘hidden’ on light chain that is 
bound to immunoglobulin) – have desired utility and 
perform effectively when compared to polyclonal anti-
body-based assays [21]. The mAbs selected for Seralite® 
were validated in a Luminex multi-plex assay format 
and found to identify all M-proteins, where present and 
detected by IFE, in over 14,000 patient specimens, and 
showed good diagnostic concordance with clinical fea-
tures, IFE of serum and urine and Freelite®. Incorporation 
of these mAbs into Seralite® yielded similarly efficacious 
results. Reported herein, we found that Seralite® detected 
all cases of LCO myeloma, and intact immunoglobulin IgA 
and IgG myeloma. These results support the view that the 
mAbs used in Seralite® are very close to the ideal of detect-
ing all FLC M-proteins from a wide assortment of patients 
and future studies independent of vendor-bias will estab-
lish Seralite® viability in the clinical setting.
Conclusions
Seralite® can be used to simultaneously and sensitively 
measure κ and λ serum FLC in 10 min. The portable nature 
of Seralite® can enable rapid FLC screening and may be 
used to accelerate decision making near-patient in the 
clinical setting.
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